- Home
- NOMA vs INKT Comparison
NOMA vs INKT Comparison
Compare NOMA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOMA | INKT |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 53.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NOMA | INKT |
|---|---|---|
| Price | $3.09 | $10.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 5.5K | ★ 11.1K |
| Earning Date | 05-22-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $8.48 |
| 52 Week High | $10.00 | $18.17 |
Technical Indicators
Market Signals| Indicator | NOMA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 44.07 |
| Support Level | $3.05 | $9.47 |
| Resistance Level | $3.95 | $12.61 |
| Average True Range (ATR) | 0.24 | 0.63 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 79.70 | 23.74 |
Price Performance
Historical ComparisonAbout NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.